



## Jagsonpal Pharmaceuticals announces Q3 FY23 Results

**Revenues grew by 11.6 % to ₹ 60.1 Crores,  
Operating EBITDA grew by 82.7 % to ₹ 14.4 Crores, EBITDA margin at 23.9%  
PAT grew by 47.1 % to ₹ 7.8 Crores**

**New Delhi, February 08, 2023: Jagsonpal Pharmaceuticals Limited** (BSE: 507789, NSE: JAGSNPHARM) today announced the financial results for the quarter ended December 31<sup>st</sup>, 2022

A detailed presentation on the performance is included as part of this press release

₹ in lakhs	Q3 FY23	Q3 FY22	Growth
Revenues	6,014	5,391	11.6 %
Operating EBITDA	1,436	786	82.7 %
Operating EBITDA Margin	23.9%	14.6%	930 bps
PAT	778	529	47.1%

Commenting on the Company's performance, Mr. Manish Gupta, Managing Director stated *"Our performance in the current quarter continues to reflect the strong brand equity and business model of Jagsonpal in India. Our focus on key brands has resulted in 11.6% growth in sales which should further accelerate going forward. Improved product mix and strong control on costs has resulted in improvements across all key margin ratios.*

*All our key brands are on growth track with the Dydrogesterone franchise (Divatrone and ProRetro) leading the way despite hyper-competition in the molecule.*

*The business added Rs. 16 crores of free cash during the quarter with our investible balance now exceeding Rs. 100 crores. This provides us the necessary wherewithal to explore inorganic strategies.*

*Our performance in last six months is a result of our consistent focus to bring Jagsonpal's financial performance in line with its peers. We now have clear roadmap for accelerating growth which should start reflecting in our performance from FY24."*

## **ABOUT JAGSONPAL PHARMACEUTICALS LIMITED**

Jagsonpal Pharmaceuticals Limited is a Delhi-based pharmaceutical company. Founded in 1978, the Company has a proven track record of 40+ years of catering to the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on the Gynecology and Orthopedic segments. Over the years, the Company has successfully built multiple brands that today hold market-leading position in respective segments. It has created a niche for itself in these value-accretive segments which resulted in mid-teens CAGR in revenues over the last four years reaching ₹ 2,176 Million in FY22. It has an extensive pan-India presence through its strong sales team of 900+ individuals.

Infinity Holdings acquired a majority stake in the company and is a joint promoter of the company. The company is listed on the National Stock Exchange Limited (NSE) and Bombay Stock Exchange Limited (BSE).

For more on the Company please visit. [www.jagsonpal.com](http://www.jagsonpal.com).

Mr. S.V. Subha Rao  
Chief Financial Officer  
Contact: [svrao@jagsonpal.com](mailto:svrao@jagsonpal.com); 01146181100

Jagsonpal Pharmaceuticals Limited  
CIN: L74899DL1978PLC009181  
T-210 J, Shahpur Jat, New Delhi – 110049